Thus, targeting the FGF-2/FGFR1/pericyte/CXCL14/TAMs axis provides a potentially novel and rational approach for treating NPC and other FGF-2–expressing tumors. The gene discussed is CXCL14; the disease is nasopharyngeal carcinoma.